摘要
心力衰竭是由于各种原因导致心肌结构和功能异常,引起心室收缩功能和/或舒张功能(充盈)受损的临床综合征。尽管目前心力衰竭的诊断和治疗已取得很大进步,但心力衰竭患者5年病死率仍可达50%。因此,迫切需要更加灵敏、特异的血清/血浆生物标志物来对心力衰竭的诊断、鉴别诊断、预后及危险分层进行辅助。目前,可溶性ST2作为一种新的生物标志物已被列入2013年ACCF/AHA指南和2014年中国心力衰竭诊断和治疗指南,且最新的美国心力衰竭指南也已将其作为推荐指标。
Heart fai lure results in myocardial structural abnormality and dysfunct ion due to various causes,and causes cl inical syndrome of damaged ventricular systolic function and/or diastolic function （filling）. Although the current diagnosis and treatment of heart failure has achieved a great progress,the mortality rate of senior patients may potentially remain at 50% in 5 years. Therefore,we urgently need more sensitive, specific serum/plasma biomarkers to assist in the diagnosis, differential diagnosis, prognosis and risk stratification of heart failure. At present, the soluble ST2 as a new biomarker, has been listed in ACCF/AHA Guidelines in 2013 and 2013 China Heart Failure Diagnosis and Treatment Guidelines, and the latest American Heart Failure Guidelines has also been recommended as indexes.
出处
《心血管病学进展》
CAS
2018年第2期214-217,共4页
Advances in Cardiovascular Diseases
基金
河北省卫生厅科研基金项目(20150108)
